IDEAS home Printed from
   My bibliography  Save this article

A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent


  • M.-K. Riviere
  • Y. Yuan
  • F. Dubois
  • S. Zohar


type="main" xml:id="rssc12072-abs-0001"> Novel molecularly targeted agents (MTAs) have emerged as valuable alternatives or complements to traditional cytotoxic agents in the treatment of cancer. Clinicians are combining cytotoxic agents with MTAs in a single trial to achieve treatment synergism and better outcomes for patients. An important feature of such combinational trials is that, unlike the efficacy of the cytotoxic agent, that of the MTA may initially increase at low dose levels and then approximately plateau at higher dose levels as MTA saturation levels are reached. Therefore, the goal of the trial is to find the optimal dose combination that yields the highest efficacy with the lowest toxicity and meanwhile satisfies a certain safety requirement. We propose a Bayesian phase I–II design to find the optimal dose combination. We model toxicity by using a logistic regression and propose a novel proportional hazard model for efficacy, which accounts for the plateau in the MTA dose–efficacy curve. We evaluate the operating characteristics of the proposed design through simulation studies under various practical scenarios. The results show that the design proposed performs well and selects the optimal dose combination with high probability.

Suggested Citation

  • M.-K. Riviere & Y. Yuan & F. Dubois & S. Zohar, 2015. "A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 64(1), pages 215-229, January.
  • Handle: RePEc:bla:jorssc:v:64:y:2015:i:1:p:215-229

    Download full text from publisher

    File URL:
    Download Restriction: Access to full text is restricted to subscribers.

    As the access to this document is restricted, you may want to search for a different version of it.


    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.

    Cited by:

    1. repec:taf:jnlasa:v:112:y:2017:i:518:p:508-520 is not listed on IDEAS
    2. repec:spr:stabio:v:10:y:2018:i:1:d:10.1007_s12561-017-9204-1 is not listed on IDEAS

    More about this item


    Access and download statistics


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:jorssc:v:64:y:2015:i:1:p:215-229. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Wiley Content Delivery). General contact details of provider: .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.